These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35969285)

  • 1. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.
    Chikermane SG; Sharma M; Abughosh SM; Aparasu RR; Trivedi MV; Johnson ML
    Breast Cancer Res Treat; 2022 Oct; 195(3):421-430. PubMed ID: 35969285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
    He X; Esteva FJ; Ensor J; Hortobagyi GN; Lee MH; Yeung SC
    Ann Oncol; 2012 Jul; 23(7):1771-80. PubMed ID: 22112968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort.
    Sieri S; Krogh V; Bolelli G; Abagnato CA; Grioni S; Pala V; Evangelista A; Allemani C; Micheli A; Tagliabue G; Schunemann HJ; Menard S; Berrino F; Muti P
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):169-76. PubMed ID: 19124495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin Use and Age-Related Macular Degeneration in Patients Without Diabetes.
    Aggarwal S; Moir J; Hyman MJ; Kaufmann GT; Flores A; Hariprasad SM; Skondra D
    JAMA Ophthalmol; 2024 Jan; 142(1):53-57. PubMed ID: 38019527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.
    Kim HJ; Kwon H; Lee JW; Kim HJ; Lee SB; Park HS; Sohn G; Lee Y; Koh BS; Yu JH; Son BH; Ahn SH
    Breast Cancer Res; 2015 May; 17(1):64. PubMed ID: 25935404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes, metformin, and breast cancer in postmenopausal women.
    Chlebowski RT; McTiernan A; Wactawski-Wende J; Manson JE; Aragaki AK; Rohan T; Ipp E; Kaklamani VG; Vitolins M; Wallace R; Gunter M; Phillips LS; Strickler H; Margolis K; Euhus DM
    J Clin Oncol; 2012 Aug; 30(23):2844-52. PubMed ID: 22689798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of diabetes and diabetes treatment with incidence of breast cancer.
    García-Esquinas E; Guinó E; Castaño-Vinyals G; Pérez-Gómez B; Llorca J; Altzibar JM; Peiró-Pérez R; Martín V; Moreno-Iribas C; Tardón A; Caballero FJ; Puig-Vives M; Guevara M; Villa TF; Salas D; Amiano P; Dierssen-Sotos T; Pastor-Barriuso R; Sala M; Kogevinas M; Aragonés N; Moreno V; Pollán M
    Acta Diabetol; 2016 Feb; 53(1):99-107. PubMed ID: 25916213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer.
    Park YM; Bookwalter DB; O'Brien KM; Jackson CL; Weinberg CR; Sandler DP
    Ann Oncol; 2021 Mar; 32(3):351-359. PubMed ID: 33516778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies.
    Wang T; Chai B; Chen WY; Holmes MD; Erdrich J; Hu FB; Rosner BA; Tamimi RM; Willett WC; Kang JH; Eliassen AH
    Int J Cancer; 2024 Jul; 155(2):211-225. PubMed ID: 38520039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes, metformin use and risk of non-Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative.
    Wang Z; Phillips LS; Rohan TE; Ho GYF; Shadyab AH; Bidulescu A; Rudick CN; Pan K; Chen Z; Luo J
    Int J Cancer; 2023 Apr; 152(8):1556-1569. PubMed ID: 36444502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
    Hosio M; Urpilainen E; Marttila M; Hautakoski A; Arffman M; Sund R; Puistola U; Läärä E; Jukkola A; Karihtala P
    Breast Cancer Res Treat; 2019 Jun; 175(3):741-748. PubMed ID: 30895533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.
    Cerne JZ; Ferk P; Frkovic-Grazio S; Leskosek B; Gersak K
    Climacteric; 2012 Feb; 15(1):68-74. PubMed ID: 22132797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.
    Schiza A; Mauri D; Fredriksson I; Anna-Karin Wennstig ; Valachis A
    Breast Cancer Res Treat; 2021 Apr; 186(3):779-789. PubMed ID: 33258078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications.
    Bashraheel SS; Kheraldine H; Khalaf S; Moustafa AA
    Biomed Pharmacother; 2023 Jun; 162():114676. PubMed ID: 37037091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes.
    Tseng CH
    Breast Cancer Res Treat; 2014 Jun; 145(3):785-90. PubMed ID: 24816805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis.
    Scarton L; Jo A; Xie Z; O'Neal LJ; Munoz Pena JM; George TJ; Bian J
    PLoS One; 2022; 17(10):e0275681. PubMed ID: 36260549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does metformin affect mammographic breast density in postmenopausal women with type 2 diabetes.
    Ozturk MA; Ozturk S; Eryilmaz M; Cinar S; Sertbas M; Ak F; Sertbas Y; Ozdemir A
    Gynecol Endocrinol; 2020 Sep; 36(9):800-802. PubMed ID: 32037910
    [No Abstract]   [Full Text] [Related]  

  • 20. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.